A review of the clinical safety
and tolerability of nomifensine
by
Stonier PD
J Clin Psychiatry 1984 Apr; 45(4 Pt 2):89-95
ABSTRACT
The tolerability and safety of nomifensine in clinical practice are reviewed
in the context of relevant topics for the second-generation antidepressants.
Nomifensine is nonsedating and impairs neither psychomotor nor cognitive
performance. It has minimal anticholinergic-like properties and is nontoxic to
the heart and cardiovascular system at therapeutic dosage. It is
nonepileptogenic. There are few relevant drug interactions, and overdose data to
date show no serious sequelae resulting from the drug itself. Side effects
include sleep disturbance, restlessness, and nausea; rare adverse reactions are
in keeping with other antidepressants. Nomifensine's profile differentiates it
from other commonly used antidepressants; the implications of this for treatment
of both common depressions and specific at-risk patients are discussed.
Dopamine
Bupropion
Amineptine
Nomifensine: profile
Nomifensine dependence
Nomifensine versus impipramine
Nomifensine, bupropion and cocaine
Nomifensine and haemolytic anaemia
Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
The Hedonistic Imperative
The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family